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Summary
Background The mechanisms by which viruses induce asthma exacerbations are not well
understood.
Objective We characterized fluctuations in nasal aspirate cytokines during naturally
occurring respiratory viral infections in children with asthma.
Methods Sixteen children underwent home collections of nasal aspirates when they were
without cold symptoms and again during self-reported respiratory illnesses. The presence
of viral infection was ascertained by multiplex PCR. Cytokines were measured using
multiplex immune assay. mRNA expression for selected markers of viral infection was
measured using RT-PCR. A cumulative respiratory symptom score was calculated for each
day of measurement. Generalized estimated equations were used to evaluate associations
between viral infection and marker elevation, and between marker elevation and symptom
score.
Results The 16 patients completed a total of 37 weeks of assessment (15 ‘well’ weeks; 22
self-assessed ‘sick’ weeks). Viral infections were detected in 3 of the ‘well’ weeks and 17
of the ‘sick’ weeks (10 rhinovirus, three coronavirus, two influenza A, two influenza B,
two respiratory syncytial virus, one parainfluenza). Compared to virus-negative well
weeks, nasal aspirate IFN-c, CXCL8/IL-8, CXCL10/IP-10, CCL5/RANTES, CCL11/eotaxin-1,
CCL2/MCP-1, CCL4/MIP-1b, CCL7/MCP-3, and CCL20/MIP3a protein levels increased
during virus-positive sick weeks. Only a subset of cytokines (IFN-c, CXCL8, CCL2, CCL4,
CCL5, and CCL20) correlated with self-reported respiratory tract symptoms. While many
aspirates were dilute and showed no mRNA signal, viral infection significantly increased
the number of samples that were positive for IFN-k1, IFN-k2/3, TLR3, RIG-I, and IRF7
mRNA.
Conclusions and clinical relevance We conclude that in children with asthma, naturally
occurring viral infections apparently induce a robust innate immune response including
expression of specific chemokines, IFNs, and IFN-responsive genes.
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Introduction
Epidemiological studies have uncovered a strong
association between viral infections, especially those
caused by rhinovirus, and exacerbations of asthma
attacks [1–3]. However, the mechanisms by which
viruses induce exacerbations of chronic airways disease
are not well understood. In response to viral infection,
the airway epithelium, and to a lesser extent immune
cells such as monocytes, macrophages, and dendritic
cells [4–7], release pro-inflammatory cytokines, interfer-
ons (IFNs), and antimicrobial substances, which in turn,
promote clearance of microorganisms, and activation of
the adaptive immune system. However, in patients with
chronic respiratory illnesses, the innate immune response
may also be responsible for disease exacerbation [8].
Although the inflammatory response to experimental
rhinovirus infection has been monitored [9–14], few
studies have examined the innate immune response of
patients with asthma to natural colds. Increases in
respiratory tract CXCL8/IL-8, CCL5/RANTES, CCL19/
MIP-1a, IL-10, CCL7/MCP-3, and CCL13/MCP-4 have
been detected [15–18]. To further examine the innate
immune response to viral infection in children with
asthma, we measured nasal aspirate cytokine levels in
16 asthmatic children before and after upper respiratory
tract infections. In contrast to the previous studies, we
examined at least three time points before and in asso-
ciation with symptomatic illness. We evaluated the
associations between viral infection and cytokine
expression, and between cytokine expression and symp-
tom score. We also examined the effects of upper
respiratory tract infection on mRNA levels of selected
markers of viral infection, including IFNs. Finally, we
evaluated a new method of virus detection using a
single polymerase chain reaction–ligation detection
reaction (PCR-LDR) multiplex assay. We hypothesized
that respiratory viral infection of children with asthma
causes robust elaboration of pro-inflammatory
cytokines and IFNs, and that the level of pro-inflamma-
tory cytokines correlates with symptom severity.
Materials and methods
Study design
We conducted an observational cohort study of 16 chil-
dren with asthma. Children were eligible for the study
if they received care from a University of Michigan
physician for asthma, were aged 6–18 years, and lived
within a 30 mile radius of Ann Arbor. Outpatients were
enrolled for 3–6 months, with the goal of assessing
cytokines at baseline and in association with at least
one viral-induced exacerbation during that period. Ini-
tial consent and first evaluation was conducted at the
University of Michigan, but all subsequent evaluations
were performed in the participant’s home. This study
was approved by the University of Michigan Institu-
tional Review Board (approval number HUM00018442).
All clinical investigations were conducted according to
principles expressed in the Declaration of Helsinki
(http://www.wma.net).
Child characteristics
At the initial assessment, parents or guardians
completed an extensive questionnaire, which included
standardized questions about presence and frequency of
asthma symptoms, an inventory of a child’s asthma
medications and current usage, and queries about
environmental exposures, and child and family
demographic information. Baseline asthma severity was
assessed using National Asthma Education and Preven-
tion Program Guidelines [19] incorporating an
adjustment for asthma controller therapy use [20].
Data and sample collection
We performed home measurements of respiratory symp-
toms and collected nasal secretions (for detection of
viral RNA by PCR and host biomarkers by PCR and
ELISA) on 3 days during a week when children were
healthy (not reporting upper respiratory tract infection
or asthma symptoms), and again during a week when
they experienced cold or flu-like symptoms. Families
were given a calendar and a simple respiratory
symptom scale and asked to mark the level of their
symptoms. We used a modified version of the respira-
tory symptom score developed by the Child Origins of
Asthma Study [21], which assessed fever, cough, nasal
symptoms, wheezing, difficulty breathing, waking up at
night with cough, and interference with usual activities.
When the patient experienced a symptomatic
respiratory illness, as defined by a symptom score of
two or higher on a scale of 0–13, the family notified
the study staff and scheduled a visit within 48 h of the
beginning of symptoms (defined as day 1 of the illness).
Information regarding impact of respiratory symptoms
on daily activities and recent use of asthma medicines
was also collected. As noted above, study technicians
visited the home every 2–3 days to retrieve additional
nasal washing samples, for a total of three visits during
the week following reporting of symptoms. The three
specific days of the week selected for analysis were
based on the convenience of the subjects and laboratory
technician. Although specimens were most often
collected on days 1, 4, and 7 of a given week, specimen
collection was sometimes compressed into a 5 or 6-day
period.
To collect a nasal lavage sample, we utilized a proto-
col developed by Powell and Shorr [22] and modified
by James Gern (University of Wisconsin, personal com-
munication). Two squirts of isotonic 0.65% sodium
chloride were instilled into the child’s nostrils (esti-
mated at < 1 mL per nostril) using a commercially
available nasal saline spray (B.F. Ascher, Lenexa, KS,
USA). The subject then blew their nose into a zippered
plastic bag, and 3 ml of M4RT viral transport medium
(Remel, Lenexa, KS, USA) was added. In general, sam-
ples were collected in the presence of study staff and
were transported from homes to the laboratory within
3 h of collection in a cooler with ice packs. However,
due to logistical issues scheduling home visits, families
were also provided with kits for independent collection
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of nasal washings specimens at home. If a visit could
not be scheduled within 48 h, families were instructed
to collect the sample, double bag the sample, place in a
tightly sealed collection box, and to keep it in the
refrigerator until the staff could collect the sample. We
required a 1 week interval between sample collections
for sequential illnesses.
Detection of respiratory viruses
Nasal aspirates were homogenized using a handheld
homogenizer to allow pipetting of viscous samples and
frozen at 70°C to allow for batched analysis. Viral
RNA and DNA were extracted using a MinElute kit
(Qiagen, Valencia, CA, USA). Samples were assessed for
the presence of viral RNA or DNA via PCR using the
Seegene Seeplex RV-12 detection kit (Seegene, Rock-
ville, MD, USA). This kit detects human parainfluenza
viruses 1, 2, and 3, human metapneumovirus, human
coronavirus 229E/NL63, and OC43, human adenovirus,
influenza viruses A and B, human respiratory syncytial
virus (RSV) A and B, and human rhinovirus A.
We also analysed specimens for respiratory viruses
using a novel polymerase chain PCR-LDR multiplex
assay [23]. The original system, which was designed to
detect influenza viruses, was expanded to include para-
influenza 1, 2, 3, 4A and 4B, coronaviruses 229E and
OC43, influenza A and B, rhinoviruses A, B, and C, ade-
noviruses A–E, metapneumovirus, and RSV A and B.
We have detected all the viruses included in this multi-
plex system in clinical samples (i.e. nasal aspirates),
with the exception of the adenoviruses, for which we
used laboratory positive controls. The viral sequences
for the multiplex assay are listed in Table 1.
Detection of nasal aspirate cytokine protein levels
Protein levels of IFN-c, CXCL8/IL-8, CXCL10/IP-10,
CCL5/RANTES, CCL11/eotaxin-1, CCL2/MCP-1, CCL4/
MIP-1b, CCL7/MCP-3, CCL19/MIP-3b, and CCL20/MIP-
3a were determined using a magnetic bead-based mul-
tiplex immune assay (Bio-Rad, Hercules, CA, USA). Our
interest on the above CC chemokines was prompted by
gene array results from RV1B-infected, ovalbumin-sen-
sitized, and -challenged mice (data not shown). IFN-a
and IFN-b levels were measured using standard ELISA
(R&D Systems, Minneapolis, MN, USA).
Detection of nasal aspirate mRNA expression
Aspirates were homogenized and mRNA extracted as
described above, using the RNEasy or the RNEasyPlus kit
(Qiagen). mRNA was analysed for CXCL8/IL-8, CXCL10/
IP10, CCL5/RANTES, CCL11/eotaxin, IFN-k1, IFN-k2/3,
IFN-a, IFN-b, ICAM-1, TLR3, MDA-5, RIG-I, and IRF7
using quantitative real time PCR using specific primers
and probes. Signals were normalized to GAPDH.
Fraction of exhaled nitric oxide in exhaled breath
(FeNO)
We assessed FeNO in exhaled breath on 3 days during
a week when the child was well, and on at least 3 days
during a viral infection. To measure FeNO, we
employed the NIOX MINO (Aerocrine, New Providence,
Table 1. Unique ligation probes employed for respiratory viral detec-
tion by polymerase chain reaction–ligation detection reaction






















Human parainfluenza 1 TCCGAGTGTAGGAAGTGGGATAAAAATT
gaaaatacactcattttcctagggtacggtg
Human parainfluenza 2 TGTGGCATAATCTTCTTTCTCAGATCTTG
tagctacatagcaatacaagacacaacctcc
Human parainfluenza 3 TAATTGACAATATCAAGTACAA
TATCTTCTATGCCTG
atgatgcataatctgatctttcatcaactttg
Human parainfluenza 4A TTGTTACTGGTAACGGACAC
gtctcaaaatttgttgatcaagacaatacaat
Human parainfluenza 4B TCGTCACTGGTACTGGCAAT
gtctcaaaatttgttgatcaagacaatacaat










RSV, respiratory syncytial virus.
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NJ, USA). Because FeNO measurement can be influ-
enced by diet and exercise, participants were asked to
refrain from eating or drinking within 1 h of their
exhaled breath assessment. Triplicate samples were
obtained to assess reliability.
Statistical design
Mean, standard deviation and interquartile range were
used to describe measured values of nasal cytokine lev-
els, nasal mRNA, and symptom score before and during
viral illnesses. Box plots were used to represent the
change in biomarkers at different points of the cold rel-
ative to the baseline. Whiskers of the boxplots represent
the minimum and maximum values. Distributions of
these continuous outcome variables were examined and
appropriate transformations taken to achieve normality.
The effects of viral illness, as defined by the Seegene
kit results, on biomarker protein levels, and of biomar-
ker level on symptom score were determined using a
generalized mixed models (PROC MIXED), with an
auto-regressive correlation structure using SAS statisti-
cal software (SAS, Cary, NC, USA). We evaluated and
adjusted for relevant covariates such as age, gender,
ethnicity/race, and nasal steroid use. Other potential
explanatory variables, such as family income, baseline
asthma severity, tobacco smoke exposure, and oral anti-
histamine use were evaluated, but not included in final
models as they were not significant predictors. For all
mRNA outcomes except IFN-b, levels were undetectable
in a large number of samples. We therefore categorized
our results into detectable/non-detectable levels, and
analysed as a binary variable using the generalized esti-
mating equation (GEE) approach with the Tobit link
[24]. We analysed IFN-b mRNA levels as a continuous
variable using the GEE approach with Identity link.
Unadjusted models are shown.
Results
Study participants
Sixteen children with physician-diagnosed asthma were
recruited. Participants ranged in age from 6 to 16 years
old, were 69% boys, 36% non-white, and reported
symptoms or medication use consistent with persistent
asthma (Table 2).
Participant respiratory illnesses
Participants completed a total of 37 weeks of assess-
ment (15 ‘well’ weeks; 22 ‘sick’ weeks). Of the 16 chil-
dren, one child did not experience any illnesses, 11
children experienced a single illness, two children
reported two illnesses, one child reported three illnesses,
and one child reported four illnesses. A total of 116
lavage samples were collected (47 during the ‘well’
weeks and 69 during the ‘sick’ weeks). The concordance
between family reports of symptoms and detection of
virus in nasal lavage specimens using the Seegene kit
was generally high. Twelve of the 15 ‘healthy weeks’
(80%) showed no viral infection, whereas three of the
well weeks (20%) were virus-positive. Six of the 22
‘sick weeks’ (27%) showed no viral infection, whereas
16 were virus-positive (73%). For the 15 ‘well’ and 22
‘sick’ weeks, 3 and 16 viral infections were detected
respectively (eight rhinovirus, three coronavirus, three
influenza A, two influenza B, two RSV, one parainflu-
enza) (Table 3). The current report focuses on the
28 weeks where there was concordance between self-
Table 2. Characteristics of children reported on carer questionnaire
(N = 16)
Child’s age at enrolment, mean (SD) 10.5 (3.3)
Female gender (%) 5 (31.25)
Child’s ethnicity (%)
African American 3 (18.75)
Arab/Middle Eastern/Chaldean 1 (6.25)
Caucasian 10 (62.5)
Multiracial 2 (12.5)
Household annual income (%)
Less than $20 000 4 (25)
$20 001–$60 000 6 (37.5)
$60 001 or more 6 (37.5)
Anyone around child smokes, yes (%) 6 (37.5)
Asthma severity (%)
Moderate-to-severe 7 (43.75)
Mild persistent 6 (37.5)
Mild intermittent 3 (18.75)
Asthma medication use (%)
Inhaled corticosteroid 13 (81.25)
Short acting bronchodilator only 2 (12.5)
Other control medication 1 (6.25)
Nasal steroid, yes (%) 4 (25)
Oral-histamine, yes (%) 8 (50)
Table 3. Virus identification in nasal lavage specimens stratified by
child self-reported health status
Frequency (%)
Healthy week Sick week Total
Coronavirus OC43 0 (0) 2 (5.4) 2 (5.4)
Coronavirus 229E/NL63 0 (0) 1 (2.7) 1 (2.7)
Influenza A 0 (0) 3 (8.1) 3 (8.1)
Influenza B 0 (0) 2 (5.4) 2 (5.4)
Parainfluenza 2 0 (0) 1 (2.7) 1 (2.7)
Respiratory syncytial virus 1 (2.7) 1 (2.7) 2 (5.4)
Rhinovirus A 3 (8.1) 6 (16.2) 9 (24.3)
No virus 12 (32.4) 6 (16.2) 18 (48.6)
Data represent absolute number of weeks (percentage of total weeks).
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reported illness and viral detection using the Seegene
kit (16 virus-positive ‘sick’ weeks, and 12 virus-nega-
tive ‘well’ weeks).
We re-tested eight positive and seven negative sam-
ples (by Seeplex) using the PCR-ligation detection mul-
tiplex assay. Twelve of 15 samples were concordant
between the two assays. Two samples were positive by
Seeplex and negative by PCR-LDR. One sample showed
RSV by Seeplex assay and coronavirus OC43 by PCR-
LDR.
Symptom scores, which qualitatively evaluated the
severity of illness, rose during the sick weeks (Fig. 1a).
Respiratory symptoms were highest at the first assess-
ment during sick weeks, 1–3 days after initial report of
illness. Children with confirmed viral illnesses experi-
enced significant increases in cough, wheeze, and chest
tightness, indicative of asthma exacerbation (Table 4).
Nasal cytokine profiles
Selected nasal aspirate cytokines were measured using
magnetic bead-based multiplex immune assay. There
were significant increases in all cytokines examined
during weeks of reported symptoms, with the single
exception of CCL7 (Table 5, Fig. 1b). This pattern was
more striking when samples with documented viral
infections were compared to those confirmed to be
virus-negative. Unadjusted estimates of the association
of confirmed viral infection and cytokine level were
highly significant (not shown) and did not change
appreciably when adjusted for age, gender, race, and
nasal steroid use.
Changes in cytokines over the course of the illness
are shown in Fig. 2. In most cases, cytokines increased
during the first 2 days of infection and persisted
throughout the week.
We also examined the relationship between cytokines
and symptom score. Unadjusted estimates of the associ-
ation of confirmed viral infection and cytokine level
with symptom score were significant for IFN-c, CXCL8,
CCL5, CCL20, CCL2, and CCL4 (Table 6). CXCL10,
CCL11, CCL19, and CCL7 cytokine levels did not corre-
late with symptom score.
We also attempted to measure IFN-a and IFN-b pro-
tein levels in the nasal aspirates by ELISA. IFN-a levels
over the lower detection limit (12.5 pg/mL) were found
in only five of 116 specimens (all virus-positive weeks).
For IFN-b, levels over the detection limit (25 pg/mL)
(a)
(b)
Fig. 1. (a) Time course of symptom scores. Skeletal box and whiskers
plot shows interquartile range (box), minimum and maximum obser-
vations (whiskers), and mean (closed circle). Average symptom scores
during the weeks of baseline assessment, when virus was not detected,
represent the healthy state. Day 1 of the viral illness was defined as
the day families reported a respiratory symptoms score  2. s1–3
represents average symptoms on days 1–3 of the illness, and so on.
Data for sick, virus-positive weeks are shown. (b) Modelled effect of
confirmed virus on cytokine concentration. Cytokine concentration
was mathematically transformed ln (y + 1) prior to modelling and
estimates are shown on this scale. Models were adjusted for age, gen-
der, race, and nasal steroid use.
Table 4. Report frequency of daily lower airways symptoms for con-
cordant weeks
Symptom
Healthy week Sick week
P-value
Virus-negative Virus-positive
N (%) N (%)
Cough
No 71 (74) 32 (27.8) < 0.001
Yes 25 (26) 83 (72.2)
Wheeze
No 89 (92.7) 87 (75.7) 0.007
Yes 7 (7.3) 28 (24.3)
Chest tightness
No 91 (94.8) 89 (77.4) 0.015
Yes 5 (5.2) 26 (22.6)
Shortness of breath
No 83 (86.5) 93 (80.9) 0.2
Yes 13 (13.5) 22 (19.1)
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were found in only 12 samples (five virus-negative,
seven virus-positive).
Nasal aspirate mRNA levels
Many aspirates were dilute and a number of specimens
showed no mRNA signal (Table 7). Nevertheless, we
detected transcripts for ICAM-1, CXCL-10, IFN-k1,
CXCL-8, RIG-I, MDA-5, TLR3, IFNk2/3, IRF7, IFN-a,
and IFN-b from patients both before and during viral
infections. We could not detect CCL5 and CCL11 mRNA
in any specimens. Finally, infection significantly
increased the number of samples that were positive for
CXCL8, IFN-k1, IFN-k2/3, TLR3, RIG-I, and IRF7
mRNA.
FeNO measurements
We measured FeNO before and during virus-positive
sick weeks (Fig. 3). There was no significant change in
FeNO measurement with viral infection.
Discussion
Viral infections are the most frequent cause of asthma
attacks [1–3]. In theory, chemokine production by
virus-infected epithelial cells induces the recruitment of
inflammatory cells to the airways, which in turn elabo-
rate cytokines and mediators capable of increasing air-
way responses. Data suggest that immune cells may
also be infected by respiratory viruses and produce
chemokines [7, 25–30]. In the present study, we found
that, during natural colds, respiratory tract cytokine
levels significantly increase in children with asthma.
Levels of a subset of cytokines correlated with the
degree and time course of respiratory symptoms. The
chemokines detected are responsible for recruitment of
a broad array of inflammatory cells including neu-
trophils, monocytes, macrophages, and eosinophils.
Finally, we detected changes in nasal lavage specimens,
which were collected at home on a repeated basis, both
before and in association with infection. Although we
did not measure cytokine levels in normal subjects,
these data show that children with asthma are appar-
ently capable of a robust cytokine response to viral
infection, even during mild exacerbations. In addition,
home collection of nasal lavage specimens appears to
be a practical tool for studying the natural history of
viral infection in children.
Our results expand upon prior work characterizing
cytokine responses detectable in respiratory secretions
of asthmatics in association with viral illnesses. Pizzi-
chini et al. [15] found that, compared to 21 days after
infection, sputum levels of CXCL8, eosinophil cationic
protein and fibrinogen from six adult asthmatics were
significantly elevated 4 days after the start of a cold-
induced exacerbation. Furthermore, CXCL8 levels corre-
lated with the number of sputum neutrophils. Teran
et al. asthma [16] found that, compared to asymptom-
atic periods, levels of major basic protein, CCL5 and
CCL19 were increased in the nasal aspirates of 26 chil-
dren during acute viral-induced exacerbations. Grissell
et al. asthma [17] found that compared to a group of
stable asthmatics, levels of CCL5 and IL-10 were signifi-
cantly elevated in the induced sputa of older children
and adults suffering from acute viral-induced asthma
exacerbations, along with neutrophils and eosinophils.
CXCL8 and CCL19 were also increased, although not
significantly. Finally, Santiago et al. [18] found that
compared to control samples, CCL7 and CCL13 were
increased in the nasal aspirates of asthmatic children 12
–24 h after upper respiratory tract infections. Chemoki-
ne levels correlated with macrophages in the nasal aspi-
rate and upper respiratory symptoms scores. In the
present study, in which patients were used as their own
controls, we confirmed the above changes in CXCL8,
CCL5, CCL19, and CCL7, and provide new data showing
significant increases in CXCL10, CCL11, CCL2, and
Table 5. Cytokine levels during healthy virus-negative and sick virus-positive weeks
Cytokine (pg/mL)
Healthy, virus-negative week (n = 12) Sick, virus-positive week (n = 15)
Mean (SD) Range Mean (SD) Range
IFN-c 12 (32) 0–114 130 (169) 0–497
CXCL8 321 (514) 22–1678 2839 (3631) 61–9888
CXCL10 7970 (14 155) 1088–48 609 27 860 (32 987) 0–140 229
CCL5 5 (6) 0–18 61 (73) 2–265
CCL11 27 (26.2) 3–73 155 (218) 4–695
CCL20 11 (14.4) 0–54 94 (193) 0–997
CCL19 35 (33) 0–101 72 (78) 0–315
CCL2 71 (99) 3–369 267 (474) 0–2277
CCL7 5 (5) 0–19 9 (13) 0–68
CCL4 23 (42) 0–220 156 (436) 0–2899
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CCL4. Importantly, we found that increases in these
chemokines were sustained throughout the week fol-
lowing viral infection.
We also examined the relationship between cytokines
and respiratory symptom score. Interestingly, we found
that some cytokines correlated with symptom score
(IFN-c, CXCL8, CCL5, CCL20, CCL2, and CCL4) whereas
others did not (CXCL10, CCL11, CCL19 or CCL7).
Although we did not examine lower airway cytokine
levels, it is tempting to speculate that the former set of
cytokines is responsible for the acute asthmatic
response to viral infection, whereas the latter set may
modulate future immune responses.
Fig. 2. Time course of nasal lavage cytokines comparing healthy week to early (s1–2), mid (s3–6), and late (s7–12) phases of self-reported sick
periods that had a confirmed viral infection.
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Based on differences in IFN-b and IFN-k production
between cells isolated from controls and asthmatic sub-
jects [31–33], it has been proposed that patients with
asthma are prone to rhinovirus-induced exacerbations
due to deficient IFN production On the other hand,
other in vitro studies showed no differences in rhinovi-
rus-induced gene expression in epithelial cells isolated
from asthmatic and healthy subjects [34, 35], and con-
trol and asthmatic subjects experimentally infected with
rhinovirus show no difference in respiratory tract viral
titre or copy number [14]. We found that viral infection
during natural colds significantly increased the levels
of IFN-c protein and IFN-k mRNA in the nasal aspi-
rates. Viral infection also significantly increased the
expression level of RIG-I and IRF-7, each of which are
Table 6. Viral presence and a subset of cytokines are independent
predictors of symptom score in unadjusted models. Cytokine concen-
trations were mathematically transformed ln (y + 1) prior to model-
ling and estimates shown are on this scale
Predictors Estimate P value

















Modelled effect of virus on cytokine
detectability
N (%) N (%) Odds ratio* (95% CI) P value
ICAM-1 No 15 (57.7) 10 (25) 2.3 (0.7, 7.6) 0.161
Yes 11 (42.3) 30 (75)
CXCL-10 No 19 (73.1) 11 (28.9) 5.4 (0.9, 31) 0.059
Yes 7 (26.9) 27 (71.1)
IFN-k1 No 24 (92.3) 26 (63.4) 7.1 (1.7, 28.7) 0.006
Yes 2 (7.7) 15 (36.6)
CXCL-8 No 7 (26.9) 1 (2.6) 13.7 (1.5, 130) 0.022
Yes 19 (73.1) 37 (97.4)
RIG-I No 11 (50) 4 (10.5) 9.4 (1.8, 47.7) 0.007
Yes 11 (50) 34 (89.5)
MDA5 No 10 (43.5) 8 (21.6) 2.5 (0.5, 12.1) 0.260
Yes 13 (56.5) 29 (78.4)
TLR3 No 7 (25) 1 (2.4) 11.5 (1.1, 118.2) 0.040
Yes 21 (75) 40 (97.6)
IFNk2/3 No 24 (88.9) 26 (63.4) 4.6 (1.1, 18.9) 0.032
Yes 3 (11.1) 15 (36.6)
IRF7 No 21 (95.5) 19 (47.5) 22.1 (4.5, 107.4) < 0.001
Yes 1 (4.5) 21 (52.5)
IFN-a No 20 (89.5) 29 (76.3) 0.318
Yes 2 (10.5) 9 (23.7)
IFN-b† No 2 (10.5) 0 (0)
Yes 20 (89.5) 38 (100)
Mean (SD) 2.0 (3.3) 0.8 (1.3) 0.111
*P-value was calculated based on the GEE method. Repeated measures were taken into account.
†Data represent mean and SD of mRNA values normalized to GAPDH.
Fig. 3. Time course of exhaled nitric oxide values. FeNO was mea-
sured using the NIOX MINO (Aerocrine, New Providence, NJ, USA).
© 2012 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 1734–1744
Cytokine responses to colds in asthma 1741
inducible by type I IFNs [36, 37]. Together, these data
suggest that asthmatic children are capable of a func-
tional IFN response. On the other hand, we failed to
detect IFN-a or IFN-b protein in nasal aspirates, and
there was no significant change in mRNA levels during
natural colds. Detection of type I IFNs in respiratory
secretions is made difficult by the low sensitivity of
commercially available assays, physiologically low lev-
els of these cytokines in biological fluids (particularly
in fluids without sufficient numbers of plasmacytoid
dendritic cells) and presence of natural inhibitors (e.g.
soluble receptors). Also, we could not compare the
results from our experimental subjects to children
without asthma.
Our finding that IRF7 mRNA is elevated after respira-
tory viral infection in children with asthma is validated
by a recent study analysing patterns of gene expression
in nasal lavage samples from children experiencing
picornavirus-induced asthma exacerbations [38].
Consistent with our previous work examining the
requirement of IRF7 for rhinovirus-induced gene
expression in cultured airway epithelial cells [39], coex-
pression analysis demonstrated IRF7 to be a major hub
connecting IFN-mediated responses in virus-induced
asthma exacerbations.
In this study, we piloted a new PCR-LDR-based
method for respiratory virus detection. Twelve of 15
samples were concordant between the two viral detec-
tion techniques; in two cases, samples were positive by
Seeplex and negative by PCR-LDR. The precise cause of
the discrepancy between the two tests is not certain,
but the Seeplex test, which relies on visual detection of
bands on agarose electrophoresis gels, may be liable to
false positives. We also optimized our PCR-LDR test for
maximum specificity, with the goal of avoiding false
positives. This may have resulted in a reduction in
sensitivity if copy number of viral nucleic acid was
low.
We measured the effect of natural colds on FeNO.
Previous studies have shown FeNO to be a reliable mea-
sure of eosinophilic airway inflammation, steroid
responsiveness, and clinical control in children and
adults with allergic asthma [40–43]. FeNO levels have
also been shown to increase during emergency steroid
treatment of acute asthma exacerbations [44, 45]. In
contrast, we found that despite increases in airway
cytokines and respiratory symptoms, there was no
increase in FeNO during natural colds in children rela-
tive to their baseline state. These data are consistent
with the notion that airway inflammation in the con-
text of viral-induced asthma exacerbations is different
in character than that associated with chronic asthma.
There are several limitations to our study. First,
although nasal sampling has the advantage of increased
safety and decreased participant burden, sputum speci-
mens more closely reflect the response of the lower
airways to viral infection. However, as noted above,
levels of IFN-c, CXCL8, CCL5, CCL20, CCL2, and CCL4
significantly correlated with respiratory symptoms,
including lower respiratory tract symptoms such as
cough, wheeze, chest tightness, and shortness of breath,
each of which are indicative of asthma exacerbation. In
addition, previous studies have found similar changes
in nasal aspirate and sputum cytokine concentrations
following viral exacerbations of asthma [16, 17].
Finally, observations demonstrate consistent effects of
nasal and bronchial provocation [46].
Second, we did not measure inflammatory cells in
the nasal aspirates. We therefore could not assess the
functional effects of chemokine release in our sub-
jects. Previous studies have shown recruitment of
neutrophils, eosinophils, and macrophages to the
respiratory tract following rhinoviral infection of
asthmatic subjects [9, 15, 17, 18, 47–50]. Also, we
cannot determine the cellular source of the mRNAs
measured in our study. Pilot analysis showed primar-
ily epithelial cells and neutrophils in the nasal aspi-
rates, suggesting that epithelial cells were the primary
source of mRNA.
Third, as noted above, we did not compare responses
of asthmatic subjects to controls. A recent study
showed that asthmatics and non-atopic subjects experi-
ence similar colds, including chemokine responses, fol-
lowing experimental rhinovirus infection [17].
Fourth, although we were able to detect significant
differences in many cytokines following upper respira-
tory tract infection, a fraction of the samples were too
dilute to detect mRNA. (There may have been other rea-
sons for the loss of RNA, for example sample ribonuc-
leases). Dilution may also affect the concentration of
measured biomarkers. We did not adjust measurements
by total protein content, as vascular leakage due to
inflammation may alter protein concentrations in chil-
dren with upper respiratory infections [51]. In our
experience, total protein is difficult to measure in many
nasal (and tracheal) aspirate specimens, even when
cytokines are readily detectable, and therefore normali-
zation for total protein does not increase the reliability
of the concentrations.
Finally, studying naturally occurring colds in chil-
dren using home-based methods inherently involves
some variability in sample timing and handling that
is not present in the controlled environment of the
laboratory. Yet this approach also offers an opportu-
nity to observe ‘real world’ scenarios. Our ability to
detect statistically significant changes in specific
mRNAs and proteins using the current study design
suggests that this is a viable approach for use in
future investigations, for example, studies examining
whether an early adjustment of asthma medications
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could abort or temper the impact of respiratory viral
infections.
We conclude that in children with asthma, naturally
occurring viral infections apparently induce a robust
innate immune response including expression of
specific chemokines, IFNs, and IFN-responsive genes.
Cytokine responses are sustained the first week follow-
ing viral infection. Future analyses of controls and
asthmatics which combine the determination of cyto-
kine responses and asthma health outcomes will provide
further insight into the cellular pathways responsible
for virus-induced asthma exacerbations.
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